Theravance Biopharma

Theravance Biopharma, Inc. aims to transform the treatment of specialty respiratory diseases through the discovery, development and commercialization of medicines. Its focus is to deliver Medicines that Make a Difference in people's lives, and it has developed the FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). The company describes itself as a place for collaborators and creative problem-solvers, and states that it is committed to creating and driving shareholder value.

Rick E Winningham has served as Chief Executive Officer of Theravance Biopharma since its spin-off from Innoviva in June 2014. He has served on the board of directors since July 2013, including as Chairman until October 2024. From October 2001 to August 2014, he served as Chief Executive Officer of Innoviva, where he also served as Chairman of the board of directors from April 2010 to October 2014.

Focused on specialty respiratory diseases and delivering Medicines that Make a Difference.

• YUPELRI (revefenacin) Inhalation Solution

  FDA-approved inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

1. 1Home | Theravance Biopharma, Inctheravance.com
2. 2Our Company | About Us | Theravance Biopharmatheravance.com
3. 3Leadership Team | Theravance Biopharmatheravance.com
4. 4Theravance Biopharma Announces Pricing of Public Offering of Ordinary Sharesprnewswire.com
5. 5Theravance Biopharma Appoints Deepika R. Pakianathan, Ph.D. to Board of Directorsprnewswire.com